The stock of Livongo Health, Inc. (NASDAQ:LVGO) has been Upgraded to Overweight from Equal-Weight by Morgan Stanley in its latest research note that was published on August 28. LVGO was given a price target of$42 by Morgan Stanley, with other Wall Street analysts also giving their reports regarding the stock. SVB Leerink, analysts launched coverage of LVGO stock with a Outperform rating, according to their flash note to investors on August 19.
Livongo Health, Inc., which has current market capitalization of above $2 Billion, published its last quarter earnings on June 30, 2019.
LVGO surged by $1.67 during the normal trading session on Thursday and reaching a high of $25.60 during the day while it closed the day at $25.28. The Livongo stock had a low trading volume of 1.33 million shares on that day, which is low compared to the average daily volume of 1.46M shares. LVGO has also lost 1.06% of its value over the past 7 days. However, the stock has declined by 0.00% in the 3 months of the year. Over the past six months meanwhile, it has lost 0.00% while it has lost 33.65% year-on date. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -44.66% from its 3 months high price. However, taking another look at LVGO will indicate that it is trading +10.49% away from its 90-day low. Looking at the bigger picture, the Livongo Health, Inc. stock has dropped by -44.66% from its 52-week high while it has surged by +10.49% from its 52-week low price.
Livongo has around 38 Billion cash on their books at the moment. This figure will have to be compared and looked into, with their current liabilities standing at $38 Billion. The Livongo stock is bringing in revenue of over 12 months, which is roughly 41 Billion. Despite all that, Livongo Health, Inc. is seeing things progressing very much as their y-o-y quarterly revenue surged by 228.09%.